Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 3Phase 3 1Phase 1 1

Status

Completed 6Recruiting 3Terminated 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1

Conditions

Neoplasms 1Endometrial Neoplasms 1Advanced Liver Cancers 1

Interventions

pembrolizumab 109Cyclophosphamide 89fludarabine 70Carboplatin 57Injections 56Bevacizumab 49Specimen Handling 43Gemcitabine 41Magnetic Resonance Spectroscopy 40Paclitaxel 39Nivolumab 38venetoclax 36Dexamethasone 35Cisplatin 34Biopsy 34Temozolomide 31Docetaxel 29Capecitabine 27atezolizumab 26Oxaliplatin 26Fluorouracil 26Pemetrexed 24Irinotecan 24Azacitidine 24abemaciclib 23toripalimab 22Fulvestrant 22fludarabine phosphate 21Rituximab 21Leucovorin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Tiragolumab × Clear all
NCT04524871 2026-05-22

MORPHEUS-LIVER

Hoffmann-La Roche

Phase 1/2 Recruiting
518 enrolled

Advanced Liver Cancers

NCT05394337 2026-05-05

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
10 enrolled
Tumor-Agnostic

Neoplasms

NCT04486352 2026-04-01

EndoMAP

Alliance Foundation Trials, LLC.

Phase 1/2 Recruiting
148 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡